Noda S, Konno S, Tanaka J, Yamada M, Yoshitake N
Department of Urology, Kurume University of Medicine, Japan.
Anticancer Res. 1990 May-Jun;10(3):709-15.
Patients 1 with an unresectable clear-cell carcinoma of the kidney was treated by intra-arterial administration of SMANCS dissolved in an oily medium, Lioidol, (SMANCS/Lipiodol). It was previously shown that targeting chemotherapy could be achieved for hepatoma by the arterially administered SMANCS/Lipiodol. In this study, SMANCS/Lipiodol was administered for renal cancer and the selective remaining of SMANCS/Lipiodol in renal cancer was observed in this patient. Patient 1, after three years and five months of repeated arterial injection of the drug, the patient's physical condition recovered sufficiently, reduction in tumor size was observed and the tumor became resectable. Patient 2 with renal carcinoma (4 cm in diameter) was treated by intra-arterial injection of SMANCS/Lipiodol and resected for prevention of postoperative recurrence. More than 90% of the tumor showed necrosis. Definite anticancer effects of the preoperative arterial administration of SMANCS/Lipiodol can be observed both clinically and histologically.
病例1为一名患有无法切除的肾透明细胞癌患者，通过动脉内注射溶解于油性介质碘油（SMANCS/碘油）中的SMANCS进行治疗。先前研究表明，通过动脉内注射SMANCS/碘油可实现对肝癌的靶向化疗。在本研究中，对该肾癌患者施用了SMANCS/碘油，并观察到SMANCS/碘油在肾癌中的选择性留存。病例1在重复动脉注射该药物三年零五个月后，患者身体状况充分恢复，观察到肿瘤尺寸减小且肿瘤变得可切除。病例2为一名患有直径4厘米肾癌的患者，通过动脉内注射SMANCS/碘油进行治疗，并为预防术后复发而进行了切除。超过90%的肿瘤出现坏死。术前动脉注射SMANCS/碘油的明确抗癌效果在临床和组织学上均可见。 1此处Patients后应接数字或具体描述，原文有误，推测此处为Patients 1 ，翻译时已修正
